Beta Bionics reported a robust first quarter for 2026, achieving $27.6 million in revenue, a 57% year-over-year increase driven by new patient starts and a growing pharmacy channel. The company highlighted a significant uptick in pharmacy penetration, with high-30s percentages of new patients accessing the islet through this channel. However, management cautioned that operational expenses are set to rise due to sales force expansion and marketing initiatives, which may pressure near-term profitability.
The gross margin improved to 59.5%, bolstered by a strong pharmacy installed base and lower material costs. Despite benefiting from one-time factors in Q1, management expects core margins to remain strong, supporting future free cash flow generation. Notably, 25%-30% of new patient starts were from type 2 diabetes, despite regulatory marketing constraints.
Investors should note that while Beta Bionics raised its full-year revenue guidance to $131 million-$136 million, the company faces challenges in marketing restrictions and rising operational costs, which could impact profitability in the near term.
Source: fool.com